2022 MPS I PILOT GRANT PROGRAM

Overview

One-year grants up to $150,000 (direct costs) will be available to develop novel treatments for MPS I. The proposed therapeutic strategies should address the unmet needs of CNS manifestations of MPS I in patients with the severe and attenuated forms of the disease. Approaches that also address the somatic manifestations of the disease including the eye, bone, connective-tissue, and heart, which not effectively treated with enzyme replacement therapy or bone marrow transplantation are welcome.

The applicant must have a proven track record in the development of novel therapeutics that progress toward clinical applications. The applicant must demonstrate utility of the proposed therapeutic platform in MPS I animal models during the course of the grant. A second year of funding is possible but should not be incorporated into the initial application.

Eligibility

All individuals holding a faculty‐level appointment at an academic institution or a senior scientific position at a non-profit institution or foundation are eligible to respond to this RFA.

Full Application (by invitation only) are Due Monday, October 17, 2022 by 8 PM EST.

To Apply:

Step 1 - Please review the "Full Application Instructions and Review Procedure" section of the 2022 MPS I Pilot Grant Program RFA Guidelines.

Step 2 - Download and complete the below forms:

Step 3 - Complete the Application Form on Submittable.

For any scientific inquiries regarding this grant please email Cara M. Weismann PhD.

For any administrative inquiries regarding this grant please email Samantha Charleston.